All In Biotech

Drug Trial Radar · NCT05001347

A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors

A Phase 2 Clinical Study of TJ004309 in Combination With Atezolizumab (TECENTRIQ®) in Patients With Advanced or Metastatic Ovarian Cancers and Selected Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Dec 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

25

Actual

Start

Nov 2, 2021

Primary completion

Feb 8, 2023

Study completion Feb 8, 2023

Sponsor

Lead sponsor
I-Mab Biopharma US LimitedIndustry
Sponsor type
Industry
First posted
Aug 11, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open label, Phase 2 study of TJ004309 in combination with atezolizumab in patients with advanced or metastatic solid tumors.

Conditions

  • Ovarian Cancer
  • Head and Neck Cancer
  • Non Small Cell Lung Cancer
  • Gastrointestinal Cancer
  • Triple Negative Breast Cancer
  • Ovarian Carcinoma

Interventions

  • TJ004309Drug

    Antibody to CD73

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To Assess the Efficacy of TJ004309 Combined With Atezolizumab in a Cohort of Patients With Platinum-resistant IO Naive Ovarian Carcinoma and a Separate Biomarker Enriched Cohort of Subjects With Selected Tumor TypesTime frame: Up to 66 weeks

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Arizona Oncology Associates

    Tucson, Arizona

  • Innovative Clinical Research Institute

    Whittier, California

  • Medical Oncology Hematology Consultants, PA

    Newark, Delaware

  • Illinois Cancer Specialists

    Arlington Heights, Illinois

  • Women's Cancer Care

    Covington, Louisiana

  • Maryland Oncology Hematology

    Rockville, Maryland

  • Laura and Isaac Perlmutter Cancer Center at NYU Langone

    New York, New York

  • Duke Cancer Center

    Durham, North Carolina

  • Tri County Hematology and Oncology Associates

    Massillon, Ohio

  • Texas Oncology - Arlington North

    Arlington, Texas

  • Texas Oncology - Austin Central

    Austin, Texas

  • Texas Oncology - Forth Worth Cancer Center

    Fort Worth, Texas

  • Texas Oncology - The Woodlands, Gynecologic Oncology

    The Woodlands, Texas

  • Virginia Cancer Specialists

    Fairfax, Virginia

  • Northwest Cancer Specialists

    Vancouver, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.